Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 1, 2012

View Archived Issues

Kyowa Hakko Kirin withdraws Japanese submission for Nesp

Tyrosine-protein kinase SYK inhibitors may counter retinoblastoma

Roche prepares new HCV NS5B inhibitors

Researchers at Gilead Sciences prepare novel sodium channel blockers

Gilead Sciences discloses new agents for HIV infection

Novel DNA-dependent protein kinase inhibitors claimed by Merck KGaA

Korean scientists prepare novel compounds with muscle relaxant activity

New treatment for rosacea designed by Galderma Pharma

Marker of multiple sclerosis duration identified in cerebrospinal fluid

Study identifies markers of treatment response in ovarian cancer

NanoViricides submits pre-IND briefing document to FDA for FluCide

Ampion demonstrates improvement in pain relief in osteoarthritis

AcelRx Pharmaceuticals gives update on ARX-01

FDA accepts NPS Pharmaceuticals' NDA for teduglutide

Spectrum Pharmaceuticals in-licenses long-acting granulocyte colony-stimulating factor

TGen and University of Arizona receive funding for cancer research

Astellas and UCB sign Japanese development and commercialization agreement for Cimzia

Janssen seeks approval for Velcade subcutaneous injection in Japan

Juventas Therapeutics reports 1-year data for JVS-100

Pfizer recaps progress of 2011

Starpharma's dendrimer-docetaxel formulation shows superiority to docetaxel in breast cancer model

FDA approves ivacaftor for rare form of cystic fibrosis

TiGenix's study of Cx-611 in rheumatoid arthritis cleared to open final cohort

Mesoblast receives FDA clearance to conduct stem cell therapy study in diabetes

NIH joins phase II tuberculosis vaccine trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...